Introduction {#Sec1}
============

Retinal artery occlusion (RAO) causes sudden, painless visual loss and leads to irreversible profound retinal damage in the majority of cases \[[@CR1]\]. Two types of RAO are commonly found: central RAO (CRAO) and branch RAO (BRAO). CRAO usually results in a dramatic, permanent decrease in visual function \[[@CR1], [@CR2]\]. BRAO leads to visual field defects corresponding to the ischemic retinal areas, and if the occlusion does not involve the fovea, visual acuity may not be impaired at all \[[@CR2]\].

CRAO is an ophthalmic emergency with treatment often recommended to start as soon as possible, as experimental data show that CRAO lasting for approximately 240 min results in massive, irreversible retinal damage \[[@CR3]\]. Since the first detailed description of CRAO in 1859 by von Graefe \[[@CR4]\], various therapies have been proposed for the acute phase of nonarteritic CRAO and claimed to be beneficial for visual outcome: anterior chamber paracentesis \[[@CR5], [@CR6]\]; ocular massage \[[@CR7]\]; intravenous injection of urokinase or plasminogen activator \[[@CR8]\]; and also local injection of plasminogen activator \[[@CR9]\]. However, Fraser and Siriwardena \[[@CR10]\] found that treatments for acute nonarteritic CRAO reported in the literature were of unproven efficacy and concluded that there was currently not enough evidence to determine which, if any, interventions had beneficial effects.

Recently, studies have shown that stimulation with weak electrical currents could have positive effects on degenerative ophthalmologic diseases such as retinitis pigmentosa (RP) \[[@CR11]\], nonarteritic anterior ischemic optic neuropathy or traumatic optic neuropathy \[[@CR12]\], and also RAO \[[@CR13]--[@CR15]\]. The mechanism for these positive effects has been suggested to be a favorable regulation of neurotropic factors; electrical stimulation has been linked to the upregulation of neurotrophins in the central and peripheral nervous systems \[[@CR16]--[@CR18]\], whereas in animal experiments, electrical stimulation has been shown to be beneficial for the survival of photoreceptors in Royal College of Surgeon's rats \[[@CR19]\] promoting the survival of photoreceptors and improving retinal function in rhodopsin P347L transgenic rabbits \[[@CR20]\], rescuing ganglion cells after optic nerve injury in Wistar rats \[[@CR21], [@CR22]\], and preserving retinal cells after light-induced retinal damage in Sprague--Dawley rats \[[@CR23]--[@CR25]\].

The neuroprotective effects of electrical stimulation have been attributed to growth factors, such as insulin-like growth factor-1 \[[@CR21], [@CR26]\], fibroblast growth factor-2 \[[@CR27], [@CR28]\], ciliary neurotrophic factor \[[@CR29], [@CR30]\], and brain-derived neurotrophic factor \[[@CR21], [@CR31]\]. Also, an overexpression of neuroprotective genes, e.g., B cell lymphoma-2 gene \[[@CR32]\], has been reported. Moreover, electrical stimulation leads to reduced expression of some tumor necrosis factor and BAX genes; the latter are related to apoptosis signaling in retinal cells \[[@CR33]\].

Another possible mechanism for the positive effects of electrical stimulation could be the associated increase in chorioretinal blood circulation, which has been demonstrated recently \[[@CR34]\].

Transcorneal electrical stimulation (TES) in patients with nonarteritic anterior ischemic optic neuropathy and traumatic optic neuropathy \[[@CR12]\], longstanding RAO \[[@CR13], [@CR14]\] and BRAO \[[@CR15]\] has demonstrated positive effects on visual acuity, visual field, and multifocal electroretinography (mfERG) in nonrandomized studies with a small number of patients.

Our recently published favorable results for TES in RP patients \[[@CR11]\] inspired us to investigate the efficacy of TES in patients suffering from RAO in a prospective, randomized, sham-controlled, partially blinded, and Good Clinical Practice (GCP)-conforming study.

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

Patients were recruited from the outpatient clinic and electronic medical records of the Centre for Ophthalmology, University of Tübingen, Germany. Inclusion criteria were age \>18 years and best corrected visual acuity (BCVA) between light perception and 0.7 logMAR.

Exclusion criteria were the presence of other ophthalmologic diseases, particularly proliferative retinal diseases, such as diabetic retinopathy, retinal or choroidal neovascularization, exudative age-related macular degeneration, silicone oil tamponade, and severe general diseases. Giant cell arteritis was ruled out by detailed history, normal serum levels of C-reactive protein, and normal age-adjusted blood sedimentation rate.

Study Design {#Sec4}
------------

The study was performed at the Centre for Ophthalmology, University of Tübingen, Germany. The protocol was approved by the local ethics committee. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

The study was conducted according to the standards of GCP, the European Union Directive for Medical Devices, and the German Medical Product Law. The trial was supervised by *STZ eyetrial*, a clinical trial unit at the Centre for Ophthalmology, University of Tübingen, which is a certified member of the European Vision Institute, Clinical Research Network (European Vision Institute Research Network, Coimbra, Portugal). *STZ eyetrial* provided study documents, performed regular monitoring visits, and controlled all study documentation including adverse events (AEs). All documents, especially inclusion criteria and study logs, were reviewed; all electronic case report form data were monitored, and source data verification was conducted according to the International Conference on Harmonisation (Geneva, Switzerland) and GCP guidelines.

Patients were seen at nine visits over a period of 17 weeks: one baseline visit (visit 1), followed by six consecutive weekly visits (visits 2--7) including application of TES (dates varied by ±2 days) and two follow-up visits (visits 8 and 9), which occurred 2 weeks (visit 8) and 11 weeks (visit 9) after visit 7 (the last visit varied by ±10 days).

After the screening visit, patients were randomly assigned to TES with 0 mA (sham), 66% of the patient's individual electrical phosphene threshold (EPT) at 20 Hz (66%), or 150% of the patient's individual EPT (150%) at 20 Hz.

Patients and technicians who performed static and kinetic perimetry, as well as full-field ERG and mfERG, were blinded to the treatment group for the entire study period. The physicians who performed all other examinations and TES were not blinded to study treatment because they were responsible for setting the stimulation parameters.

Clinical Examinations {#Sec5}
---------------------

At all nine visits, ophthalmologic examinations were performed: BCVA assessment using a Snellen projector (SCP-660^®^, Nidek Inc., Freemont, CA, USA) at a viewing distance of 6 m; retro-illuminated Early Treatment Diabetic Retinopathy Study charts (ETDRS, ETDRS^®^ Visual Acuity Tester, Steinbeis-Transferzentrum, Tübingen, Germany) at a viewing distance of 2 m distance; for both Snellen and ETDRS examinations, a viewing distance of 1 m was used if the visual acuity at 2 and 6 m was immeasurable. Also performed were slit-lamp biomicroscopy, fundus examination, and Goldmann applanation tonometry (AT 900^®^, Haag-Streit, Wedel, Germany). At visits 1, 2, 5, 8, and 9, static and kinetic perimetry were recorded. Perimetry was performed with an Octopus 900^®^ perimeter (Haag-Streit, Wedel, Germany); background luminance was 10 cd/m² using white-on-white stimuli and a fast threshold strategy (German Adaptive Thresholding Estimation) \[[@CR35]\] up to 85° eccentricity. For kinetic perimetry, white stimuli (Goldmann III4e with constant angular velocity of 3°/s) up to 90° eccentricity were presented every 15°. Isopter and scotoma areas (in degrees²) were quantified using the machine's built-in software algorithm. As a quality criterion for kinetic perimetry, the blind spot was detected with at least five stimuli (Goldmann I4e) at 2°/s.

All patients underwent initial visual field testing at the screening visit and once again at visit 1. Generally, only the test at visit 1 was recorded.

At visits 1, 5, 8, and 9, ERG and mfERG were conducted according to the standards of the International Society for Clinical Electrophysiology of Vision (ISCEV) \[[@CR36], [@CR37]\]. ERG was recorded using an Espion E2^*®*^ (Diagnosys LLC, Cambridge, UK) and a ColorDome^*®*^ (Diagnosys LLC, Cambridge, UK). The protocol consisted of six steps with stimulus strengths from 0.01 to 10 cd.s/m^2^ and 4 ms duration (white 6500K). Three single-flash stimuli were used under scotopic conditions (stimulus strength 0.01 cd.s/m^2^; rod response), 3 cd.s/m^2^ (standard flash, combined rod-cone response), and 10 cd.s/m^2^ (high-intensity flash) as a scotopic protocol. A single flash stimulus with 3 cd.s/m^2^ (single-flash cone response) and a 30 Hz flicker were chosen as a photopic protocol. The impedance level was \<10 kΩ. A wide-range band-pass filter (from 0.3 to 300 Hz) was applied using the machine's built-in algorithm. ERG potentials \<5 μV were excluded from the analysis.

To perform mfERG, a VerisTM^*®*^-System (Electro-Diagnostic Imaging Inc., Redwood City, CA, USA; software version Veris Science TM 5.1) and a 21′′ screen ("UHR21L," Nortech Imaging Technologies, Plymouth, MN, USA; resolution 1,024 × 768) positioned 32 cm in front of the patient were used. The stimulus consisted of 61 scaled hexagonal elements presented with alternating black (5 cd/m^2^) and white (100 cd/m^2^) fields covering a central visual field of 60 × 55°. The built‐in algorithm allowed recordings between 10 and 100 Hz, amplified by a factor of 200,000.

All electrophysiologic examinations and electrical stimulation were performed using a single-use sterile DTL electrode \[[@CR38]\] (Diagnosys, Liverpool, UK) and a gold-plated cup electrode (LKC Technologies Inc., Gaithersburg, MD, USA) as a counter electrode (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Transcorneal electrical stimulation was performed using **a** a sterile single-use DTL electrode and **b** a commercially-available neurostimulator programmed with **c** biphasic current pulses of 10 ms duration (5 ms positive, directly followed by 5 ms negative) at a frequency of 20 Hz

Cornea and conjunctiva were anesthetized with 0.4% oxybuprocaine hydrochloride (Conjuncain EDO^®^, Bausch & Lomb, Rochester, NY, USA). Pupils were dilated with 0.5% tropicamide (Mydriaticum Stulln^®^, Stulln, Germany).

Determination of EPT and TES {#Sec6}
----------------------------

TES and assessment of EPT were performed using a neurostimulator (Twister^®^; Dr. Langer GmbH, Waldkirch, Germany) and a single-use sterile DTL-electrode (Fig. [1](#Fig1){ref-type="fig"}). A gold-plated cup electrode was used as a counter electrode, and fixed on the ipsilateral temple (Fig. [1](#Fig1){ref-type="fig"}). EPT was determined at all nine visits over a range of frequencies.

The threshold was defined as the minimal electric current that elicited phosphene perception anywhere in the visual field. An alternative forced choice method was used for verification. The neurostimulator was modified by the manufacturer to limit current output to 10 mA with increments starting from 1 μA.

Impedance of the electrodes was tested each time prior to stimulation and at various intervals during stimulation using the machine's built-in algorithm; impedance did not exceed 5 kΩ.

Measurements were performed in darkness with a very dim indirect light produced by the shielded computer screen. To avoid dark adaptation, the light was switched on periodically (ca. every 60--90 s) \[[@CR39]\]. Full darkness was necessary to allow perception of the very subtle phosphenes. The threshold at 20 Hz was determined three times, and the average was taken at each study visit for the calculation of individual stimulation strength according to the treatment group. TES was applied with 10 ms rectangular biphasic current pulses (5 ms positive, directly followed by 5 ms negative) at 20 Hz for 30 min once a week for 6 consecutive weeks.

Data Analysis {#Sec7}
-------------

Statistical analyses were performed using the JMP^®^ statistical software (version 8.02, SAS Institute, Cary, NC, USA). ERG data analysis was performed using previously described software \[[@CR40]\]; the slope of the initial part of the a-wave was calculated and compared to evaluate photoreceptor activity \[[@CR41]\]. Intra-individual differences were calculated for each patient between baseline and follow-up visits. A comparison between treatment groups was then performed using the method of restricted maximum likelihood (REML) to estimate the development of parameters under treatment for each group. To compare groups, the Tukey--Kramer post hoc test analysis was applied with a significance level of *P* \< 0.05.

Results {#Sec8}
=======

Thirteen patients with nonarteritic RAO were enrolled (12 patients with CRAO and one patient with BRAO, age range 25--84 years, median 74 years). In total, 20 patients were screened for study participation and seven patients were excluded from the study because they were not able to deliver repeatable results in the visual field examination due to poor fixation. RAO was diagnosed 10 days to 17 months (median 11 months) prior to inclusion. Table [1](#Tab1){ref-type="table"} shows detailed characteristics for all patients. The numbers of patients assigned to the treatment groups were: 0 mA TES (sham), *n* = 3; 66% of the patients' individual EPT at 20 Hz (60%), *n* = 5, and 150% of the patients' individual EPT at 20 Hz (150%), *n* = 5.Table 1Patient characteristicsPatientAge (years)GenderOphthalmologic diagnosisTreated eyeTreatment group (% of EPT)Time from RAO to TES (days)VA (Snellen), visit 1VA (Snellen), visit 9General disorders/characteristics174FCRAOR150%18HM1/35Arterial hypertension, hypercholesterolemia274FCRAOR150%64PLO1/20Diabetes mellitus type II, arterial hypertension, tobacco smoking369MCRAOR150%1121/201/20Diabetes mellitus type II, arterial hypertension, coronary heart disease, two coronary stents484FCRAOL150%10HM1/35Diabetes mellitus type II, arterial hypertension, obesity, heart failure, pacemaker565FCRAOL150%1421/101/15Aortic and mitral valve biologic prostheses660MCRAOL66%2181/251/20Arterial hypertension775FCRAOL66%20HMHMDiabetes mellitus type II, arterial hypertension, coronary heart disease, three coronary stents, pacemaker875MCRAOR66%306/606/15Arterial hypertension925MCRAOL66%5101/206/120Patent foramen ovale1069FCRAOR66%1531/151/10Diabetes mellitus type II, arterial hypertension, carotid stenosis1171FCRAORSham27HM1/15Diabetes mellitus type II, arterial hypertension, early myocardial infarction, absolute arrhythmia1281FBRAOLSham146/7.56/7.5Diabetes mellitus type II, arterial hypertension, mitral regurgitation, aortic valve stenosis, carotid stenosis1365FCRAORSham11HM1/15Arterial hypertensionVA (Snellen at 6 m or 1 m) was recorded as perception of light only (PLO), detection of hand movement (HM), or ability to count fingers (CF) at baseline (visit 1) and 9 weeks after TES (visit 9)*BRAO* branch retinal artery occlusion, *CRAO* central retinal artery occlusion, *EPT* electrical phosphene threshold, *F* female, *L* left, *M* male, *R* right, *RAO* retinal artery occlusion, *TES* transcorneal electrical stimulation, *VA* visual acuity

All 13 patients completed the entire study. TES using DTL-electrodes was well tolerated, as reported previously \[[@CR11], [@CR39]\]. No ocular or systemic AEs were observed, except for foreign-body sensation after TES (*n* = 3).

All raw data and REML values are listed in Table [2](#Tab2){ref-type="table"}; excerpts follow in this section. At the beginning, three patients reported phosphenes only at some of the tested frequencies (20 and 40 Hz) despite stimulation currents up to 4 mA; a level at which unpleasant sensations, such as a twitch in the eyelid, were reported. In the course of the study in two of these patients, determination of EPT was possible at all tested frequencies, whereas in one patient phosphenes could only be evoked at 20 Hz at the end of the study.Table 2Raw data for the tested parameters for each of the three treatment groups (transcorneal electrical stimulation with sham, 66% and 150% of the individual phosphene threshold at 20 Hz, respectively) as well as the changes detected under treatment (calculated using a REML method; *P* \< 0.05, Tukey--Kramer)TestSubtest \[unit raw data; unit REML\]GroupRaw data^a^REMLVisit 1^b^Visit 5Visit 8Visit 9*P* valueMean95% CI intervalScotopic ERGSF a-wave ampl. \[μV; μV\]Sham109.29 ± 11.01124.69 ± 30.30128.37 ± 36.15170.40 ± 20.260.0832.253.53, 60.9666%162.86 ± 96.46166.22 ± 88.94163.26 ± 107.9143.92 ± 30.08−5.61−28.62, 17.40150%145.50 ± 40.52147.68 ± 43.92141.36 ± 21.72139.28 ± 30.79−5.31−28.96, 18.18SF a-wave impl. \[ms; ms\]Sham19.67 ± 2.0820.33 ± 1.5319.67 ± 2.0819.00 ± 3.000.55−0.01−0.69, 0.69,66%18.00 ± 1.8717.40 ± 1.6718.40 ± 2.7918.00 ± 2.12−0.08−0.61, 0.45150%19.40 ± 0.8919.00 ± 1.8719.80 ± 1.1018.20 ± 0.84−0.41−0.94, 0.12SF b-wave ampl. \[μV; μV\]Sham179.35 ± 93.88198.72 ± 122.1187.97 ± 76.25223.57 ± 109.90.3924.10−16.33, 64.5366%248.40 ± 172.7235.44 ± 168.2231.04 ± 139.9249.06 ± 83.70−10.30−42.22, 21.63150%135.47 ± 62.43132.27 ± 56.51142.48 ± 57.46127.97 ± 50.30−2.28−34.58, 30.01SF b-wave impl. \[ms; ms\]Sham61.67 ± 6.5163.33 ± 8.9655.67 ± 4.6249.33 ± 5.030.11−5.76−11.16, −0.3566%55.20 ± 4.8253.20 ± 4.9255.80 ± 11.9952.60 ± 9.71−1.51−5.09, 2.07150%53.60 ± 8.2947.40 ± 8.7959.90 ± 3.5655.20 ± 5.891.06−2.54, 4.65Photopic ERGSF a-wave ampl. \[μV; μV\]Sham18.80 ± 4.4023.18 ± 15.2221.51 ± 13.8124.06 ± 9.620.404.11−5.05, 13.2866%18.26 ± 11.7832.28 ± 27.0917.57 ± 10.2918.84 ± 6.674.56−2.65, 11.78150%19.93 ± 7.4919.03 ± 5.5017.96 ± 7.7017.86 ± 3.46−1.80−9.09, 5.50SF a-wave impl. \[ms; ms\]Sham18.00 ± 1.0018.00 ± 1.0017.00 ± 2.6517.33 ± 1.530.21−0.56−1.97, 0.8566%15.80 ± 2.2816.40 ± 2.0716.20 ± 1.3015.80 ± 2.050.35−0.76, 1.46150%16.00 ± 1.0017.20 ± 0.4518.00 ± 1.4116.00 ± 1.221.05−0.07, 2.17SF b-wave ampl. \[μV; μV\]Sham47.12 ± 26.3365.42 ± 57.3959.79 ± 21.1967.64 ± 34.630.1117.152.19, 32.1166%67.28 ± 25.8660.11 ± 35.6056.11 ± 26.9285.10 ± 45.11−0.02−11.51, 11.46150%35.59 ± 18.5432.93 ± 17.2535.94 ± 14.0131.09 ± 14.73−1.97−13.54, 9.59SF b-wave impl. \[ms; ms\]Sham37.67 ± 4.5138.33 ± 4.7336.00 ± 2.6536.33 ± 2.520.25−0.78−2.08, 0.5166%34.00 ± 3.5434.00 ± 3.0834.00 ± 3.7433.60 ± 3.78−0.14−1.14, 0.87150%36.80 ± 3.9636.40 ± 5.5035.40 ± 1.9534.60 ± 3.13−1.32−2.33, −0.31Visual acuitySnellen \[logMAR; logMAR\]Sham1.40 ± 1.081.00 ± 0.781.07 ± 0.851.00 ± 0.820.890.300.01, 0.6066%1.34 ± 0.421.14 ± 0.301.00 ± 0.411.12 ± 0.600.230.01, 0.46150%1.68 ± 0.501.44 ± 0.301.18 ± 0.271.32 ± 0.200.290.06, 0.52VFArea \[deg^2^; deg^2^\]Sham7,975 ± 3,230^b^6,595 ± 5,5017,361 ± 5,2716,471 ± 5,4730.24−9.10−1,739.00, 1,720.0066%9,941 ± 3,6309,138 ± 3,6419,743 ± 3,38411,522 ± 2,6301,09159.00, 2,123.00150%1,387 (*n* = 1)^b^2,077 ± 1,9612,203 ± 2,8963,862 ± 3,759NANAMean sensitivity \[dB; dB\]Sham5.90 ± 6.083.87 ± 7.496.90 ± 6.034.40 ± 7.710.281.50−0.80, 3.7766%5.25 ± 3.527.10 ± 5.358.48 ± 6.689.43 ± 7.582.700.98, 4.43150%1.50 (*n* = 1)^b^7.37 ± 7.746.55 ± 10.027.80 ± 10.48−0.08−4.39, 4.24Mean defect \[dB; dB\]Sham13.05 ± 7.8515.90 ± 9.3914.10 ± 9.7215.33 ± 9.680.25−1.53−2.92, −0.1266%15.60 ± 4.0714.25 ± 6.4913.18 ± 8.5212.63 ± 8.81−1.69−3.25, −1.1715%20.90 (*n* = 1)^b^14.33 ± 8.8815.50 ± 9.5512.87 ± 10.89−1.18−0.11, 1.05Phosphene thresholdSensitivity at 20 Hz \[mA; mA\]Sham0.65 ± 0.480.52 ± 0.350.57 ± 0.440.57 ± 0.480.510.12−0.18, 0.4166%0.66 ± 0.650.46 ± 0.330.43 ± 0.280.51 ± 0.410.16−0.04, 0.36150%1.41 ± 1.501.37 ± 1.510.91 ± 0.430.77 ± 0.400.290.09, 0.49Multifocal ERGAmp. Ring 1 \[μV; μV\]Sham21.03 ± 18.5113.93 ± 14.5312.40 ± 19.338.63 ± 9.570.13−9.38−18.40, −0.3566%11.52 ± 8.0212.04 ± 7.1711.34 ± 8.2710.46 ± 10.55−0.24−7.23, 6.75150%5.38 ± 7.075.08 ± 6.228.64 ± 7.898.10 ± 7.071.89−5.10, 8.88Impl. Ring 1 \[ms; ms\]Sham27.73 ± 14.6728.87 ± 15.7930.00 ± 15.2128.03 ± 15.300.821.23−12.69, 15.1666%30.16 ± 10.2531.14 ± 11.2033.48 ± 11.7729.48 ± 8.021.21−9.58, 11.99150%18.98 ± 19.5921.82 ± 12.0626.48 ± 15.3324.00 ± 14.465.12−5.67, 15.91Amp. Ring 2 \[μV; μV\]Sham8.40 ± 7.317.30 ± 6.006.03 ± 7.897.90 ± 7.110.29−1.32−4.12, 1.4766%7.72 ± 2.687.96 ± 1.485.82 ± 4.046.01 ± 3.78−1.09−3.26, 1.07150%3.16 ± 3.463.06 ± 3.234.74 ± 3.824.38 ± 3.020.90−1.27, 3.07Impl. Ring 2 \[ms; ms\]Sham28.60 ± 12.4726.10 ± 12.4728.30 ± 13.0129.97 ± 17.020.64−0.48−14.29, 13.3366%32.82 ± 3.9234.48 ± 3.9133.98 ± 12.3029.82 ± 9.27−0.06−10.76, 10.64150%20.14 ± 18.9122.16 ± 10.0328.16 ± 13.4625.00 ± 15.155.63−5.06, 16.33Amp. Ring 3 \[μV; μV\]Sham6.03 ± 2.975.50 ± 5.165.00 ± 2.886.17 ± 5.060.56−0.48−1.87, 0.9166%4.96 ± 1.985.52 ± 0.943.64 ± 3.003.52 ± 2.41−0.73−1.81, 0.34150%3.14 ± 2.032.64 ± 1.303.24 ± 1.813.58 ± 2.380.01−1.06, 1.09Impl. Ring 3 \[ms; ms\]Sham36.90 ± 2.5525.23 ± 13.9136.50 ± 3.7837.73 ± 5.650.93−3.74−12.28, 4.7966%34.64 ± 2.6534.80 ± 5.9933.16 ± 11.5729.30 ± 12.30−2.22−8.83, 4.39150%34.32 ± 13.8932.32 ± 10.1534.64 ± 14.6330.32 ± 11.77−1.89−8.50, 4.72Amp. Ring 4 \[μV; μV\]Sham4.27 ± 2.194.97 ± 2.273.90 ± 1.873.90 ± 3.460.82−0.01−1.14, 1.1266%4.10 ± 1.864.12 ± 1.212.86 ± 1.864.20 ± 1.81−0.37−1.25, 0.50150%2.62 ± 1.841.92 ± 1.292.54 ± 1.802.26 ± 1.73−0.38−1.26, 0.50Impl. Ring 4 \[ms; ms\]Sham36.37 ± 3.1835.97 ± 4.8836.40 ± 6.7237.73 ± 5.880.440.33−3.76, 4.4366%36.30 ± 4.2736.98 ± 4.8132.30 ± 10.2435.96 ± 4.82−1.22−4.39, 1.95150%36.82 ± 16.2634.14 ± 14.4035.32 ± 14.2832.80 ± 13.31−2.73−5.90, 0.44Amp. Ring 5 \[μV; μV\]Sham3.67 ± 2.514.03 ± 2.183.90 ± 2.213.33 ± 1.930.660.09−1.38, 1.5966%4.06 ± 1.733.60 ± 1.313.26 ± 0.963.70 ± 1.15−0.54−1.68, 0.60150%2.70 ± 2.231.68 ± 1.232.26 ± 1.512.20 ± 1.59−0.65−1.79, 0.49Impl. Ring 5 \[ms; ms\]Sham36.93 ± 4.9037.70 ± 4.6937.77 ± 4.8640.53 ± 8.240.501.73−3.91, 7.3866%38.14 ± 4.5438.48 ± 6.6035.30 ± 4.1536.00 ± 4.56−1.55−5.92, 2.8215%36.14 ± 16.7333.98 ± 14.3334.32 ± 13.0234.14 ± 12.20−1.99−6.36, 2.38*Ampl.* amplitude, *CI* confidence interval, *ERG* electroretinography, *Impl*. implicit time, *REML* restricted maximum likelihood, *SF* standard flash, *VF* visual field^a^Results from visit 1, 5, 8, and 9 are given as the mean ± standard deviation^b^For VF, some values are given for visit 2 because VF was not recordable in five patients at baseline. REML estimates are given as the mean and 95% upper and lower confidence intervals. Electrical stimulation was performed between visits 2 and 7. SF = 3 cd.s/m^2^

At all visits and in all patients, the lowest EPT was found at 20 Hz. EPT (mean ± standard deviation \[SD\]) at baseline was 0.97 ± 1.06 mA at 20 Hz, 1.43 ± 1.36 mA at 40 Hz, 1.83 ± 1.51 mA at 60 Hz, 1.63 ± 1.42 mA at 80 Hz, 1.82 ± 1.50 mA at 3 Hz, 1.59 ± 1.36 mA at 6 Hz, and at 1.82 ± 1.50 mA 9 Hz. The stimulation current ranged from 0.1 to 1.75 mA.

No statistically significant differences were detected in visual field parameters (Table [2](#Tab2){ref-type="table"}). The mean defect, the mean sensitivity in static visual field, and the area of kinetic visual field did not differ significantly between the groups; calculation of the changes in the area of the kinetic visual field in the 150% treatment group failed because the visual field was not recordable in four patients at baseline (Table [2](#Tab2){ref-type="table"}). However, in some of the treated patients, an enlargement of visual field area was observed. Figure [2](#Fig2){ref-type="fig"} shows fundus photographs and the development of visual field area in two selected patients in the 150% treatment group. RAO was diagnosed in the first of these patients at 7 months and in the second of these patients at 6 months before study enrollment.Fig. 2Fundus photographs and development of visual field (VF) area in two selected patients from the group treated with 150% of the individual electric phosphene threshold at 20 Hz. In the treated patients, an enlargement of VF area was observed, but statistical significance was not reached. Retinal artery occlusion was diagnosed in patient 1 (*left*) at approximately 7 months and in patient 2 (*right*) at approximately 6 months prior to study enrollment. *LE* right eye, *RE* right eye

During study visits no significant differences were observed between the groups for amplitudes and implicit times in the ERG measurements under dark- or light-adapted conditions (Table [2](#Tab2){ref-type="table"}). There were, however, statistically significant changes (*P* = 0.03) in the a-wave slope of the high-intensity flash (10 cd.s/m²) under scotopic conditions with increased values in the follow-up as compared to baseline in the 150% treatment group with mean ± standard error (SE) of 0.46 ± 0.7 μV/ms, and decreased values in the 66% and sham treatment groups of −2.1 ± 0.7 and −1.74 ± 0.9 μV/ms, respectively.

Discussion {#Sec9}
==========

Recently, studies with TES in humans have shown that TES is safe and can exhibit positive effects in patients with degenerative retinal diseases \[[@CR11]--[@CR15]\]. In particular, a sham-controlled pilot study in RP showed some significant effects after only 6 weeks of TES treatment \[[@CR11]\].

In 2007, Inomata et al. \[[@CR13]\] published a case description of three patients with longstanding RAO. Patients were treated with TES once a month for a period of 3 months (stimulation current up to 1.1 mA, 20 Hz biphasic pulses, 30 min, contact lens electrode). After treatment the authors noted an improvement in visual acuity of \>0.2 logMAR in two cases and an enlargement of the visual field in all three cases.

In 2010, Robles-Camarillo et al. \[[@CR14]\] investigated the effects of TES on low vision in patients with CRAO. In the 2-month study, nine patients were split into three groups: control, TES treatment for 45 min twice per month, and TES treatment for 45 min once per week. TES was applied with contact lens electrodes, although stimulation parameters were not given in this publication. The group's results showed an improvement in visual acuity and increased responses of the a- and b-wave in the ERG data in all stimulated patients.

More recently, Oono et al. \[[@CR15]\] in 2011 described an improvement in mfERG responses in five patients with BRAO. A single TES treatment was delivered using contact lens electrodes; the current strength ranged between 0.5 and 0.9 mA with biphasic pulses at 20 Hz while the duration of each session was 30 min.

To the authors' knowledge, the present study is the first randomized, sham-controlled, and partially blinded study to investigate TES as a potential treatment in patients with RAO. The specific stimulation parameter was chosen due to the fact that the lowest EPT was observed at 20 Hz. This trough for EPT at 20 Hz was also found in healthy subjects, and patients with other retinal diseases, such as RP, nonarteritic anterior ischemic optic neuropathy, Stargardt's disease, and primary open-angle glaucoma \[[@CR42]\].

The stimulation current, calculated from the individual EPT at 20 Hz, ranged in the present study from 0.10 to 1.75 mA. In their studies with RAO patients, Inomata et al. \[[@CR13]\] and Oono et al. \[[@CR15]\] used stimulation currents ranging from 0.50 to 1.10 mA. These values are, remarkably, comparable to the values used in the present study, despite significant differences in techniques. The stimulation time of 30 min in the present study was based on that used in previous studies \[[@CR11]--[@CR13], [@CR15]\]. The frequency of application in the present study (once weekly in 6 consecutive weeks) was selected on the basis that more intensive stimulation (vs. the three-times monthly TES treatment used by Inomata et al. \[[@CR13]\]) could potentially have more positive effects.

In the 150% treatment group, a statistically significant increase in the scotopic a-wave slope was detected. As the a-wave slope is regarded as the electrophysiologic representation of the phototransduction process by the photoreceptors \[[@CR43]--[@CR46]\], these results indicate an improvement in photoreceptor activity during TES treatment. All other tested parameters failed to show statistically significant improvements. A failure to reach statistical significance may have been due to the very small sample size, with only three to five patients in each group. It may, however, also have been due to the short study period of only six stimulation sessions in an attempt to treat very profound retinal damage; such damage usually has a very poor prognosis. In contrast to this, in the present study with 24 RP patients \[[@CR11]\], significant improvements were found in clinically relevant parameters, such as visual field area and scotopic b-wave amplitude, under the same study parameters, but had the chance to examine a considerably larger study population. Statistical significance would not have been reached with smaller sample sizes as recalculations of the present data have shown. In the present study subgroup analysis of data was not done because the groups were small, although an improvement in two longstanding cases is in accordance with previous reports by Inomata et al. \[[@CR13]\]. It should be emphasized here that the cases included in the Inomata et al. \[[@CR13]\] study and all other previous studies mentioned \[[@CR14], [@CR15]\] were based on uncontrolled series with a limited strength of evidence. The possibility that the present findings may have been biased by a potential imbalance in the study groups, such as differing extent and severity of retinal damage, and inconsistent timing of TES treatment, cannot be completely eliminated.

As a statistically significant clinical effect from the present data could not be shown, TES cannot be currently recommended as a treatment for CRAO or BRAO. Hayreh and Zimmerman \[[@CR1]\] reported that without any treatment, an improvement in visual acuity and visual field is observed in only 6% of eyes with nonarteritic CRAO. However, the visual outcome in CRAO patients using existing treatments is unsatisfactory; various studies of new treatments for CRAO have shown no significant differences in the visual outcome between treated and untreated patients \[[@CR6], [@CR47]--[@CR49]\]. Considering the lack of scientifically justifiable treatment options for BRAO and CRAO, and taking into account the limitations of the present study (short duration, small sample size) and the statistically significant improvement detected in a-wave slopes, further investigation is warranted to explore the potential of TES for these conditions. Any further studies on the therapeutic value of TES should retain the stringent use of a sham control, as used in the present study, and maintain study groups as homogeneously as possible. It may be possible that the initiation of treatment with TES very shortly after the onset of RAO might have a clearer effect on the course of the disease.

In conclusion, TES provides several potential advantages over intravitreal injections or surgical interventions, e.g., minimal invasiveness. Furthermore, TES most probably generates low treatment costs, and the simplicity of the concept also means considerable ease of use for both the examiner and the patient. Therefore, it is conceivable that patients may be allowed a stimulation device at home.
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